GILD250110C89000
- 0.67
- -1.61-70.61%
Gilead Sciences Newsroom
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Gilead Sciences Hits 6-week Low
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Unusual Options Activity: IVZ, HIMS and Others Attract Market Bets, IVZ V/OI Ratio Reaches 198.8
EST Jan 8th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Express News | Corrected-Buzz-Pharma Group Galapagos Jumps 11% on Planned Split
Looking Into Gilead Sciences's Recent Short Interest
Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Hookipa Shareholder Gilead Sciences to Back Poolbeg Merger
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Citi's Themes: Top Stocks in AI, Leisure, Fin-tech, Video Gaming, Etc. Vs. Their SA Quant Ratings
Gilead Sciences, Inc. (GILD): A Bull Case Theory
Express News | Gilead's new HIV drug has been approved domestically: it requires administration twice a year, and trials show a 96% reduction in the infection rate.
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer